SG11201610770PA - Quinolizinone derivatives as pi3k inhibitors - Google Patents
Quinolizinone derivatives as pi3k inhibitorsInfo
- Publication number
- SG11201610770PA SG11201610770PA SG11201610770PA SG11201610770PA SG11201610770PA SG 11201610770P A SG11201610770P A SG 11201610770PA SG 11201610770P A SG11201610770P A SG 11201610770PA SG 11201610770P A SG11201610770P A SG 11201610770PA SG 11201610770P A SG11201610770P A SG 11201610770PA
- Authority
- SG
- Singapore
- Prior art keywords
- pi3k inhibitors
- quinolizinone derivatives
- quinolizinone
- derivatives
- pi3k
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2182MU2014 | 2014-07-04 | ||
| PCT/IB2015/054958 WO2016001855A1 (en) | 2014-07-04 | 2015-07-01 | Quinolizinone derivatives as pi3k inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201610770PA true SG11201610770PA (en) | 2017-01-27 |
Family
ID=53716533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201610770PA SG11201610770PA (en) | 2014-07-04 | 2015-07-01 | Quinolizinone derivatives as pi3k inhibitors |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9944639B2 (es) |
| EP (1) | EP3164400A1 (es) |
| JP (1) | JP6291601B2 (es) |
| KR (1) | KR20170082490A (es) |
| CN (1) | CN106470996B (es) |
| AP (1) | AP2016009661A0 (es) |
| AU (1) | AU2015283671B2 (es) |
| BR (1) | BR112017000132A2 (es) |
| CA (1) | CA2954231A1 (es) |
| CL (1) | CL2017000006A1 (es) |
| CO (1) | CO2017000011A2 (es) |
| CR (1) | CR20160600A (es) |
| CU (1) | CU24428B1 (es) |
| EA (1) | EA201692557A1 (es) |
| GE (1) | GEP20186934B (es) |
| HK (1) | HK1232227A1 (es) |
| IL (1) | IL249674B (es) |
| MA (1) | MA40250A (es) |
| MX (1) | MX2017000208A (es) |
| PE (1) | PE20170640A1 (es) |
| PH (1) | PH12017500007A1 (es) |
| SG (1) | SG11201610770PA (es) |
| SV (1) | SV2017005354A (es) |
| UA (1) | UA115296C2 (es) |
| WO (1) | WO2016001855A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2879809T3 (es) * | 2014-11-01 | 2021-11-23 | Shanghai Fochon Pharmaceutical Co Ltd | Ciertos inhibidores de proteínas quinasas |
| WO2017103825A1 (en) | 2015-12-18 | 2017-06-22 | Lupin Limited | Quinolizinone derivatives as pi3k inhibitors |
| US10751339B2 (en) | 2018-01-20 | 2020-08-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
| US20220112217A1 (en) * | 2018-08-21 | 2022-04-14 | Medshine Discovery Inc. | Pyrazolopyrimidine derivative and use thereof as pi3k inhibitor |
| JP2022530049A (ja) * | 2019-04-23 | 2022-06-27 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 統合ストレス応答経路のモジュレーター |
| WO2021164789A1 (zh) * | 2020-02-21 | 2021-08-26 | 南京明德新药研发有限公司 | 一种吡唑并嘧啶类化合物的晶型及其应用 |
| WO2021233227A1 (en) * | 2020-05-16 | 2021-11-25 | Fochon Pharmaceuticals, Ltd. | Compounds as protein kinase inhibitors |
| CA3227902A1 (en) * | 2021-08-09 | 2023-02-16 | Jr. David St. Jean | Compounds that inhibit pi3k isoform alpha and methods for treating cancer |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| SI2223922T1 (sl) | 2000-04-25 | 2016-04-29 | Icos Corporation | Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme |
| WO2005016348A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
| US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
| WO2005067901A2 (en) | 2004-01-08 | 2005-07-28 | Michigan State University | Methods for treating and preventing hypertension and hypertension-related disorders |
| CA2566436C (en) | 2004-05-13 | 2011-05-10 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
| HUE030950T2 (en) | 2004-05-13 | 2017-06-28 | Icos Corp | Quinazolinones as 3-kinase delta inhibitors of human phosphatidylinositol |
| CA2567883A1 (en) | 2004-05-25 | 2005-12-15 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells |
| CN101123968A (zh) | 2004-06-04 | 2008-02-13 | 艾科斯有限公司 | 肥大细胞病的治疗方法 |
| WO2006089106A2 (en) | 2005-02-17 | 2006-08-24 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
| DK2004654T3 (da) | 2006-04-04 | 2013-07-22 | Univ California | Pyrazolopyrimidin derivater til anvendelse som kinase antagonister |
| KR20090087027A (ko) | 2006-11-13 | 2009-08-14 | 일라이 릴리 앤드 캄파니 | 염증 질환 및 암의 치료를 위한 티에노피리미디논 |
| AU2008231385B2 (en) | 2007-03-23 | 2012-02-02 | Amgen Inc. | Delta3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase ( PI3K) inhibitors |
| EP2132207A2 (en) | 2007-03-23 | 2009-12-16 | Amgen Inc. | Heterocyclic compounds and their uses |
| HUE028954T2 (en) | 2007-03-23 | 2017-01-30 | Amgen Inc | Heterocyclic compounds and their use |
| GEP20125635B (en) | 2007-11-13 | 2012-09-10 | Icos Corp | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| US8703777B2 (en) | 2008-01-04 | 2014-04-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
| JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン， エルエルシー | 複素環キナーゼ阻害剤 |
| EP2411391A1 (en) | 2009-03-24 | 2012-02-01 | Gilead Calistoga LLC | Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
| ES2548253T3 (es) | 2009-04-20 | 2015-10-15 | Gilead Calistoga Llc | Métodos para el tratamiento de tumores sólidos |
| JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン， エルエルシー | 複素環式化合物およびその使用 |
| WO2010151735A2 (en) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Heterocyclic compounds and their uses |
| MX2011013510A (es) | 2009-06-25 | 2012-03-07 | Amgen Inc | Compuestos heterociclicos y sus usos. |
| CA2765823A1 (en) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Tricyclic heterocyclic compounds as mediators of p13k activity |
| SI2448938T1 (sl) * | 2009-06-29 | 2014-08-29 | Incyte Corporation Experimental Station | Pirimidinoni kot zaviralci pi3k |
| MX2012000817A (es) | 2009-07-21 | 2012-05-08 | Gilead Calistoga Llc | Tratamiento para desordenes del higado con inhibidores pi3k. |
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| CA3022722A1 (en) | 2009-11-05 | 2011-05-12 | Rhizen Pharmaceuticals S.A. | Pi3k protein kinase modulators |
| WO2011058112A1 (en) | 2009-11-12 | 2011-05-19 | Ucb Pharma S.A. | Fused bicyclic pyrazole derivatives as kinase inhibitors |
| EP2513109A1 (en) | 2009-12-18 | 2012-10-24 | Amgen Inc. | Heterocyclic compounds and their uses |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| US9193721B2 (en) | 2010-04-14 | 2015-11-24 | Incyte Holdings Corporation | Fused derivatives as PI3Kδ inhibitors |
| AU2011255218B2 (en) | 2010-05-21 | 2015-03-12 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| CA2802484A1 (en) | 2010-06-11 | 2011-12-15 | Gilead Calistoga Llc | Methods of treating hematological disorders with quinazolinone compounds in selected patients |
| WO2012003264A1 (en) | 2010-06-30 | 2012-01-05 | Amgen Inc. | Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors |
| MX2012014983A (es) | 2010-06-30 | 2013-04-24 | Amgen Inc | Quinolinas como inhibidores pi3k. |
| JP2013530236A (ja) | 2010-07-01 | 2013-07-25 | アムジエン・インコーポレーテツド | Ｐｉ３ｋ活性の阻害剤としての複素環式化合物およびその用途 |
| AU2011272853A1 (en) | 2010-07-01 | 2013-01-10 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of PI3K activity |
| MX2012015134A (es) | 2010-07-02 | 2013-05-06 | Amgen Inc | Compuestos heterociclicos y su uso como inhibidores de actividad de pi3k. |
| WO2012040634A1 (en) | 2010-09-24 | 2012-03-29 | Gilead Calistoga Llc | Atropisomers of pi3k-inhibiting compounds |
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| US20140031355A1 (en) | 2010-11-04 | 2014-01-30 | Amgen Inc. | Heterocyclic compounds and their uses |
| EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
| AU2011329806A1 (en) | 2010-11-17 | 2013-05-30 | Amgen Inc. | Quinoline derivatives as PIK3 inhibitors |
| CA2822590A1 (en) | 2010-12-23 | 2012-06-28 | Amgen Inc. | Heterocyclic compounds and their uses |
| JP2014501790A (ja) | 2011-01-10 | 2014-01-23 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | イソキノリノンの調製方法及びイソキノリノンの固体形態 |
| AP2013007158A0 (en) | 2011-03-11 | 2013-10-31 | Gilead Calistoga Llc | Combination therapies for hematologic malignancies |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| TW201311683A (zh) * | 2011-04-29 | 2013-03-16 | Exelixis Inc | 使用吡啶并嘧啶酮ｐｉ３ｋ／ｍｔｏｒ抑制劑治療淋巴瘤之方法 |
| TW201306842A (zh) * | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法 |
| CN102838601A (zh) | 2011-06-24 | 2012-12-26 | 山东亨利医药科技有限责任公司 | 选择性磷酰肌醇3-激酶δ抑制剂 |
| CN102838600A (zh) | 2011-06-24 | 2012-12-26 | 山东亨利医药科技有限责任公司 | 苯基喹唑啉类PI3Kδ抑制剂 |
| AR088218A1 (es) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos utiles como inhibidores de pi3k |
| EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| RU2014111823A (ru) | 2011-08-29 | 2015-10-10 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
| WO2013052699A2 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
| WO2013082540A1 (en) | 2011-12-02 | 2013-06-06 | Gilead Calistoga Llc | Compositions and methods of treating a proliferative disease with a quinazolinone derivative |
| WO2013116562A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Calistoga Llc | Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile |
| MX355299B (es) | 2012-03-13 | 2018-04-11 | Respivert Ltd | Inhibidores de cinasa de fosfoinositida 3 cristalina. |
| WO2013152150A1 (en) | 2012-04-04 | 2013-10-10 | Amgen Inc. | Heterocyclic compounds and their uses |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| DK3260455T3 (da) | 2012-07-04 | 2019-06-11 | Rhizen Pharmaceuticals S A | Selektive pi3k delta-hæmmere |
| WO2014015523A1 (en) | 2012-07-27 | 2014-01-30 | Hutchison Medipharma Limited | Novel heteroaryl and heterocycle compounds, compositions and methods |
| SG11201501173SA (en) | 2012-08-08 | 2015-05-28 | Kbp Biosciences Co Ltd | PI3Kδ INHIBITOR |
| EP2884980A1 (en) | 2012-08-14 | 2015-06-24 | Gilead Calistoga LLC | Combination therapies for treating cancer |
| SG11201502032VA (en) | 2012-10-16 | 2015-05-28 | Almirall Sa | Pyrrolotriazinone derivatives as pi3k inhibitors |
| WO2014060431A1 (en) | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
| DK2914296T4 (da) | 2012-11-01 | 2022-01-03 | Infinity Pharmaceuticals Inc | Behandling af cancere under anvendelse af PI3-kinase-isoform-modulatorer |
| US20140120060A1 (en) | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors |
| CA2895782C (en) | 2012-12-21 | 2017-08-22 | Gilead Calistoga Llc | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors |
| JP6207100B2 (ja) | 2012-12-21 | 2017-10-04 | ギリアード カリストガ エルエルシー | イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤 |
| WO2014106800A2 (en) | 2013-01-04 | 2014-07-10 | Aurigene Discovery Technologies Limited | Substituted 2-amino pyrimidine derivatives as kinase inhibitors |
| AR094797A1 (es) | 2013-02-15 | 2015-08-26 | Almirall Sa | Derivados de pirrolotriazina como inhibidores de pi3k |
| WO2014128612A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
| TW201522341A (zh) | 2013-03-15 | 2015-06-16 | Respivert Ltd | 化合物 |
| US9216985B2 (en) | 2013-03-28 | 2015-12-22 | Scifluor Life Sciences, Inc. | 3-aryl-2-((arylamino)methyl)quinazolin-4-(3H)-ones |
| JP6030783B2 (ja) | 2013-06-14 | 2016-11-24 | ギリアード サイエンシーズ， インコーポレイテッド | ホスファチジルイノシトール３−キナーゼ阻害剤 |
| CN105431437B (zh) | 2013-07-02 | 2020-03-10 | 理森制药股份公司 | PI3K蛋白激酶抑制剂，特别是δ抑制剂和/或γ抑制剂 |
| CN104447727B (zh) | 2013-09-02 | 2018-04-27 | 广东东阳光药业有限公司 | 取代的氨基嘧啶类化合物及其使用方法和用途 |
| KR20160060100A (ko) | 2013-09-22 | 2016-05-27 | 칼리토르 사이언시즈, 엘엘씨 | 치환된 아미노피리미딘 화합물 및 이용 방법 |
| SG11201607705XA (en) | 2014-03-19 | 2016-10-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
| CN105130966B (zh) | 2014-05-07 | 2019-05-24 | 广东东阳光药业有限公司 | 炔基化合物及其使用方法和用途 |
| WO2015175579A1 (en) | 2014-05-15 | 2015-11-19 | Calitor Sciences, Llc | Alkynyl compounds and methods of use |
| AU2015274635B2 (en) | 2014-06-13 | 2018-04-19 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| CN106459005A (zh) | 2014-06-13 | 2017-02-22 | 吉利德科学公司 | 磷脂酰肌醇3‑激酶抑制剂 |
| NZ726052A (en) | 2014-06-13 | 2018-04-27 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
| US9765060B2 (en) | 2014-06-24 | 2017-09-19 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| ES2879809T3 (es) | 2014-11-01 | 2021-11-23 | Shanghai Fochon Pharmaceutical Co Ltd | Ciertos inhibidores de proteínas quinasas |
| CN105130984B (zh) | 2015-09-23 | 2017-03-29 | 前湾医药科技（深圳）有限公司 | 一种咪唑并吡啶类化合物与在制备pi3k抑制剂中的应用 |
-
2015
- 2015-07-01 SG SG11201610770PA patent/SG11201610770PA/en unknown
- 2015-07-01 WO PCT/IB2015/054958 patent/WO2016001855A1/en active Application Filing
- 2015-07-01 MX MX2017000208A patent/MX2017000208A/es unknown
- 2015-07-01 US US15/323,565 patent/US9944639B2/en not_active Expired - Fee Related
- 2015-07-01 EA EA201692557A patent/EA201692557A1/ru unknown
- 2015-07-01 CU CU2016000195A patent/CU24428B1/es unknown
- 2015-07-01 MA MA040250A patent/MA40250A/fr unknown
- 2015-07-01 UA UAA201701013A patent/UA115296C2/uk unknown
- 2015-07-01 AU AU2015283671A patent/AU2015283671B2/en not_active Ceased
- 2015-07-01 PE PE2016002810A patent/PE20170640A1/es unknown
- 2015-07-01 EP EP15739683.9A patent/EP3164400A1/en not_active Withdrawn
- 2015-07-01 GE GEAP201514408A patent/GEP20186934B/en unknown
- 2015-07-01 CN CN201580036482.9A patent/CN106470996B/zh not_active Expired - Fee Related
- 2015-07-01 CR CR20160600A patent/CR20160600A/es unknown
- 2015-07-01 BR BR112017000132A patent/BR112017000132A2/pt not_active Application Discontinuation
- 2015-07-01 AP AP2016009661A patent/AP2016009661A0/en unknown
- 2015-07-01 CA CA2954231A patent/CA2954231A1/en not_active Abandoned
- 2015-07-01 JP JP2016575554A patent/JP6291601B2/ja not_active Expired - Fee Related
- 2015-07-01 KR KR1020177003196A patent/KR20170082490A/ko unknown
-
2016
- 2016-12-20 IL IL249674A patent/IL249674B/en not_active IP Right Cessation
-
2017
- 2017-01-03 SV SV2017005354A patent/SV2017005354A/es unknown
- 2017-01-03 CL CL2017000006A patent/CL2017000006A1/es unknown
- 2017-01-03 PH PH12017500007A patent/PH12017500007A1/en unknown
- 2017-01-03 CO CONC2017/0000011A patent/CO2017000011A2/es unknown
- 2017-06-16 HK HK17106009.7A patent/HK1232227A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017000132A2 (pt) | 2018-01-09 |
| AP2016009661A0 (en) | 2016-12-31 |
| US20170137421A1 (en) | 2017-05-18 |
| GEP20186934B (en) | 2018-12-10 |
| JP6291601B2 (ja) | 2018-03-14 |
| CU20160195A7 (es) | 2017-05-10 |
| IL249674B (en) | 2019-06-30 |
| SV2017005354A (es) | 2018-10-05 |
| CN106470996A (zh) | 2017-03-01 |
| CL2017000006A1 (es) | 2017-06-02 |
| MX2017000208A (es) | 2017-05-01 |
| AU2015283671B2 (en) | 2018-07-05 |
| KR20170082490A (ko) | 2017-07-14 |
| HK1232227A1 (zh) | 2018-01-05 |
| CA2954231A1 (en) | 2016-01-07 |
| MA40250A (fr) | 2017-05-10 |
| US9944639B2 (en) | 2018-04-17 |
| CU24428B1 (es) | 2019-06-04 |
| CR20160600A (es) | 2017-03-07 |
| PH12017500007A1 (en) | 2017-05-15 |
| JP2017519786A (ja) | 2017-07-20 |
| UA115296C2 (uk) | 2017-10-10 |
| CN106470996B (zh) | 2019-02-22 |
| PE20170640A1 (es) | 2017-05-26 |
| WO2016001855A1 (en) | 2016-01-07 |
| CO2017000011A2 (es) | 2017-04-10 |
| AU2015283671A1 (en) | 2017-02-02 |
| EP3164400A1 (en) | 2017-05-10 |
| IL249674A0 (en) | 2017-02-28 |
| EA201692557A1 (ru) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287113A (en) | smyd inhibitors | |
| IL246785A0 (en) | Benzimidazole-2-amines as midh1 inhibitors | |
| PL3218378T3 (pl) | Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych | |
| HK1226398A1 (zh) | 作為midh1抑制劑的苯並咪唑-2-胺 | |
| IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| HK1232227A1 (zh) | 作為 抑制劑的喹嗪酮衍生物 | |
| HUE050450T2 (hu) | Fluoralkil-fluorén-származékok | |
| IL248773A0 (en) | History of naphthyridinedione | |
| HK1250161B (zh) | 6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途 | |
| IL252866B (en) | History of imidazopyridazine as pi3k beta inhibitors | |
| IL248629A0 (en) | Substances containing diheteroaryl conjugated to cycloalkyl and their uses | |
| IL258438B (en) | 2-Aminoquinoline derivatives as p70s6 kinase inhibitors | |
| HK1252767A1 (zh) | 作為eaat3抑制劑的吡唑-吡啶衍生物 | |
| PL3119744T3 (pl) | Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu | |
| GB201418154D0 (en) | Inhibitors | |
| SG10201404643XA (en) | Nitrogen Containing Heterocyclic PI3K δ Inhibitor |